Flutiform misses in COPD study

Vectura Group plc (LSE:VEC) said Flutiform fluticasone/ formoterol missed the primary endpoint in a Phase III study to treat chronic obstructive pulmonary disease (COPD), and said partner Mundipharma International Ltd. (Cambridge, U.K.) will no longer pursue EU approval for Flutiform in the indication.

Flutiform was not superior to formoterol monotherapy on annualized rates of moderate and severe COPD exacerbations. The study enrolled 1,767 COPD patients. ...